Antiretroviral News and Research RSS Feed - Antiretroviral News and Research

HIV-positive people with early-stage cancer less likely to get cancer treatment

HIV-positive people with early-stage cancer less likely to get cancer treatment

HIV-infected people diagnosed with cancer are two to four times more likely to go untreated for their cancer compared to uninfected cancer patients, according to a new, large retrospective study from researchers in Penn Medicine's Abramson Cancer Center and the National Cancer Institute (NCI) published online ahead of print in the Journal of Clinical Oncology. [More]
ASPIRE completes patient enrollment in Phase III trial of vaginal ring for HIV prevention

ASPIRE completes patient enrollment in Phase III trial of vaginal ring for HIV prevention

ASPIRE, one of two Phase III trials of a promising method for preventing HIV in women - a vaginal ring worn for a month at a time - has completed enrollment of participants, with 2,629 women from 15 clinical research sites in Malawi, South Africa, Uganda and Zimbabwe now taking part in the study. [More]
Study questions whether health system, government policies can meet needs of people aging with HIV

Study questions whether health system, government policies can meet needs of people aging with HIV

As the first people with HIV grow old, a new study from St. Michael's Hospital questions whether the health care system and other government policies are prepared to meet their complex medical and social needs. [More]
Study finds link between high CD4 cell counts and reduced ischemic stroke risk in people with HIV

Study finds link between high CD4 cell counts and reduced ischemic stroke risk in people with HIV

A 15-year study found that HIV-positive individuals had a 40 percent increased risk of ischemic stroke, however stroke rates were nearly the same for HIV-positive individuals with high CD4 cell counts as for HIV-negative subjects. [More]
Janssen, Viiv Healthcare to develop single tablet regimen for maintenance treatment of HIV

Janssen, Viiv Healthcare to develop single tablet regimen for maintenance treatment of HIV

Janssen R&D Ireland Ltd announced today that they have entered into a collaboration with ViiV Healthcare to develop and commercialize a new single tablet regimen containing Janssen's Non-Nucleoside Reverse Transcriptase Inhibitor rilpivirine (marketed as EDURANT®) and ViiV's Integrase Inhibitor dolutegravir(marketed as TIVICAY®) as the sole active ingredients for the maintenance treatment of people living with Human Immunodeficiency Virus (HIV). [More]
Mylan launches Risedronate Sodium Tablets USP, 150 mg

Mylan launches Risedronate Sodium Tablets USP, 150 mg

Mylan Inc. today announced that it has launched Risedronate Sodium Tablets USP, 150 mg, the generic version of Warner Chilcott's Actonel Tablets. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment and prevention of osteoporosis in postmenopausal women. [More]
Mylan launches generic version of Bristol-Myers Squibb's Paraplatin Injection

Mylan launches generic version of Bristol-Myers Squibb's Paraplatin Injection

Mylan Inc. today announced that it has launched Carboplatin Injection, 50 mg/5 ml, in multi-dose vials, which is the generic version of Bristol-Myers Squibb's Paraplatin® Injection. [More]
Researchers map transmission network of human immunodeficiency virus in San Diego

Researchers map transmission network of human immunodeficiency virus in San Diego

Researchers at the University of California, San Diego School of Medicine have mapped the transmission network of human immunodeficiency virus (HIV) in San Diego. [More]
Scientists identify new way to reactivate latent HIV

Scientists identify new way to reactivate latent HIV

A team of scientists at the Gladstone Institutes has identified a new way to make latent HIV reveal itself, which could help overcome one of the biggest obstacles to finding a cure for HIV infection. [More]
Merck enrolls first patient in reformulated raltegravir Phase 3 trial for treatment of HIV-1 infection

Merck enrolls first patient in reformulated raltegravir Phase 3 trial for treatment of HIV-1 infection

Merck, known as MSD outside the United States and Canada, today announced that the first patient has been enrolled in the company's global Phase 3 clinical trial, ONCEMRK. [More]
State highlights: NYC plan for treating mentally ill; Kan. town gets abortion services again; Iowa medical marijuana

State highlights: NYC plan for treating mentally ill; Kan. town gets abortion services again; Iowa medical marijuana

Mayor Bill de Blasio has asked several of his commissioners and aides to provide him with a plan by September to reduce the rate of incarceration among New Yorkers with mental illness. The effort, which City Hall will announce on Monday, is the administration's first major criminal justice initiative. Named the Task Force on Behavioral Health and the Criminal Justice System, it will include recommendations from the police and correction commissioners, the Manhattan district attorney, hospital administrators and judges (Goldstein, 6/1). [More]
CIRM grants $5.6 million to develop HIV/AIDS therapeutic using Sangamo's ZFN genome-editing technology

CIRM grants $5.6 million to develop HIV/AIDS therapeutic using Sangamo's ZFN genome-editing technology

Sangamo BioSciences, Inc. announced that the California Institute for Regenerative Medicine (CIRM) has granted a $5.6 million Strategic Partnership Award to fund clinical studies at City of Hope to develop a potentially curative ZFP Therapeutic for HIV/AIDS based on the application of Sangamo's zinc finger nuclease (ZFN) genome-editing technology in hematopoietic stem/progenitor cells (HSPCs). [More]
Longer looks: 'Abandoning' patients; commiting people with mental illness; treating PTSD

Longer looks: 'Abandoning' patients; commiting people with mental illness; treating PTSD

For years I had tried and failed to understand why so many of my physician colleagues persisted in ordering tests, procedures, and treatments that seemed to provide no benefit to patients and even risked harming them. [More]
Mylan launches generic version of GlaxoSmithKline's Malarone Tablets

Mylan launches generic version of GlaxoSmithKline's Malarone Tablets

Mylan Inc. today announced that it has launched Atovaquone and Proguanil Hydrochloride Tablets, 62.5 mg/25 mg and 250 mg/100 mg, the generic version of GlaxoSmithKline's Malarone® Tablets. [More]

Testing for STI co-infections may improve HIV prevention in Africa

To maximize HIV prevention efforts in South Africa and perhaps the broader region, public health officials should consider testing for other sexually transmitted infections when they test for HIV, according to a new paper in the journal Sexually Transmitted Infections. [More]
BioTime receives ISO 13485:2003 certification for development of BioTime HyStem hydrogels

BioTime receives ISO 13485:2003 certification for development of BioTime HyStem hydrogels

BioTime, Inc. today announced that it has received ISO 13485:2003 certification from BSI (British Standards Institution) for design, development, manufacture, and distribution of BioTime HyStem® hydrogels for cell delivery applications. [More]
Study: Children born with HIV more likely to develop resistance to antiretroviral drugs than adults

Study: Children born with HIV more likely to develop resistance to antiretroviral drugs than adults

Children born with HIV are far more likely to develop resistance to antiretroviral drugs than adults, according to a new Tulane University School of Medicine study. [More]
Dolutegravir drug offers added benefit in HIV patients

Dolutegravir drug offers added benefit in HIV patients

Dolutegravir has been approved since January 2014 in combination with other antiretroviral drugs for the treatment of human immunodeficiency virus (HIV) infected adults and adolescents above 12 years of age. [More]
Two new studies aim to change HIV infections in children, maternal deaths due to HIV

Two new studies aim to change HIV infections in children, maternal deaths due to HIV

HIV has been transformed into a chronic, manageable disease for most people living with HIV in the United States, where mother-to-child transmission of HIV is now a rare occurrence. [More]
U.S. urges daily pill for those at risk of AIDS

U.S. urges daily pill for those at risk of AIDS

The recommendation could transform AIDS prevention from reliance on condoms to a regimen that relies on an antiretroviral drug. Meanwhile, a report analyzes the costs and benefits of treating prison inmates for hepatitis C and a study finds that nearly half of American adults take prescriptions. [More]